Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (3): 460-466. doi: 10.19723/j.issn.1671-167X.2021.03.004

Previous Articles     Next Articles

Effectiveness of different screening strategies for cardiovascular diseases prevention in a community-based Chinese population: A decision-analytic Markov model

LIU Qiu-ping1,CHEN Xi-jin2,WANG Jia-min1,LIU Xiao-fei2,SI Ya-qin1,LIANG Jing-yuan1,SHEN Peng3,LIN Hong-bo3,TANG Xun1,Δ(),GAO Pei1,2,Δ()   

  1. 1. Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing 100191, China
    2. Center for Real-world Evidence Evaluation, Peking University Clinical Research Institute, Beijing 100191, China
    3. Yinzhou District Center for Disease Control and Prevention, Ningbo 315101, Zhejiang, China
  • Received:2021-02-27 Online:2021-06-18 Published:2021-06-16
  • Contact: Xun TANG,Pei GAO E-mail:tangxun@bjmu.edu.cn;peigao@bjmu.edu.cn
  • Supported by:
    National Natural Science Foundation of China(81973132);National Natural Science Foundation of China(81961128006);National Key Research and Development Program of China(2020YFC2003503)

RICH HTML

 49   

PDF (PC)

455

Abstract:

Objective: To evaluate the potential effectiveness of different screening strategies for cardiovascular diseases prevention in a community-based Chinese population from economically developed area of China. Methods: Totally 202 179 adults aged 40 to 74 years without cardiovascular diseases at baseline (January 1, 2010) were enrolled from the Chinese electronic health records research in Yinzhou (CHERRY) study. Three scenarios were considered: the screening strategy based on risk charts recommended by the 2020 Chinese guideline on the primary prevention of cardiovascular diseases in Chinese adults aged 40-74 years (Strategy 1); the screening strategy based on the prediction for atherosclerotic cardiovascular disease risk in China (China-PAR) models recommended by the 2019 Guideline on the assessment and management of cardiovascular risk in China in Chinese adults aged 40-74 years (Strategy 2); and the screening strategy based on the China-PAR models in Chinese adults aged 50-74 years (Strategy 3). According to the guidelines, individuals who were classified into medium- or high-risk groups after cardiovascular risk assessment by the corresponding strategies would be introduced to lifestyle intervention, while high-risk population would take medication in addition. Markov model was used to simulate different screening scenarios for 10 years (cycles), using parameters mainly from the CHERRY study, as well as published data, Meta-analyses and systematic reviews for Chinese populations. The life year gained, quality-adjusted life year (QALY) gained, number of cardiovascular disease events/deaths could be prevented and number needed to be screened (NNS) were calculated to compare the effectiveness between the different strategies. One-way sensitivity analysis on uncertainty of cardiovascular disease incidence rate and probabilistic sensitivity analysis on uncertainty of distributions for the hazard ratios were conducted. Results: Compared with non-screening strategy, QALYs gained were 1 433 [95% uncertainty interval (UI): 969-1 831], 1 401 (95%UI: 936-1 807), and 716 (95%UI: 265-1 111) for the Strategies 1,2, and 3; and the NNS per QALY in the above strategies were 141 (95%UI: 110-209), 144 (95%UI: 112-216), and 198 (95%UI: 127-529), respectively. The Strategies 1 and 2 based on different guidelines showed similar effectiveness, while more benefits were found for screening using China-PAR models in adults aged 40-74 years than those aged 50-74 years. The results were consistent in the sensitivity analyses. Conclusion: Screening for cardiovascular diseases in Chinese adults aged above 40 years seems effective in coastal developed areas of China, and the different screening strategies based on risk charts by the 2020 Chinese guideline on the primary prevention of cardiovascular diseases or China-PAR models by the 2019 Guideline on the assessment and management of cardiovascular risk in China may have similar effectiveness.

Key words: Cardiovascular diseases, Screening, Markov model

CLC Number: 

  • R181.32

Figure 1

Markov model diagram for screening of cardiovascular diseases CVD, cardiovascular diseases; P1, probability from CVD-free status to alive with CVD status; P2, probability from CVD-free status to CVD death status; P3, probability from alive to non-CVD death status; P4, probability to stay alive without CVD; P5, probability from alive with CVD status to CVD death status; P6, probability to stay alive with CVD."

Table 1

Parameters related to effect sizes and the data sources in Markov model"

Items Cardiovascular diseases incidence Cause-specific mortality on cardiovascular diseases
HR SD Data source HR SD Data source
Strategy 1
Low risk 0.64 0.01 Estimated from the current study 1
Medium risk 1.41 0.03 Estimated from the current study 1
High risk 1.89 0.04 Estimated from the current study 1.17 0.02 Cohort study[10]
Strategy 2
Low risk 0.48 0.01 Estimated from the current study 1
Medium risk 1.71 0.04 Estimated from the current study 1
High risk 3.30 0.08 Estimated from the current study 1.17 0.02 Cohort study[10]
Strategy 3
Low risk 0.66 0.02 Estimated from the current study 1
Medium risk 1.68 0.03 Estimated from the current study 1
High risk 3.33 0.07 Estimated from the current study 1.17 0.02 Cohort study[10]
Lifestyle intervention
Weight control 0.93 0.05 Meta-analysis[11] 0.93 0.16 Meta-analysis[11]
Smoke cession 0.85 0.02 Meta-analysis[12] 0.72 0.13 Cohort study[13]
Salt reduction 0.81 0.08 Meta-analysis[14] 0.66 0.14 Meta-analysis[14]
Statin and antihypertensive 0.70 0.17 Clinical trial[15] 0.82 0.13 Clinical trial[15]
Cardiovascular diseases history 1.37 0.03 Cohort study[16] 3.12 0.10 IPD-meta[17]

Table 2

Baseline characteristics of study population by gender"

Characteristics Men(n=93 127) Women(n=109 052) P value
Age/years, $\bar{x} \pm s$ 55.8 ± 8.6 54.8 ± 8.4 <0.001
Urban, n (%) 24 821 (26.6) 31 572 (28.9) <0.001
Smoker, n (%) 41 570 (44.6) 2 219 (2.0) <0.001
Family history of ASCVD, n (%) 858 (0.9) 739 (0.7) <0.001
Diabetes mellitus, n (%) 8 486 (9.1) 11 042 (10.1) <0.001
CKD stage 3/4, n (%) 278 (0.3) 346 (0.3) 0.448
Hypertension, n (%) 28 819 (30.9) 36 153 (33.2) <0.001
Anti-hypertensive treatment, n (%) 3 779 (5.2) 5 680 (4.0) <0.001
SBP/mmHg, $\bar{x} \pm s$ 131.3 ± 16.1 130.9 ± 16.8 <0.001
DBP/mmHg, $\bar{x} \pm s$ 81.9 ± 9.6 80.9 ± 9.6 <0.001
BMI/(kg/m2), $\bar{x} \pm s$ 23.4 ± 2.7 23.4 ± 3.0 0.005
Waist circumference/cm, $\bar{x} \pm s$ 83.7 ± 8.1 80.0 ± 8.3 <0.001
Total cholesterol/(mmol/L), $\bar{x} \pm s$ 4.8 ± 1.0 5.1 ± 1.0 <0.001
HDL-C/(mmol/L), $\bar{x} \pm s$ 1.3 ± 0.4 1.4 ± 0.3 <0.001
LDL-C/(mmol/L), $\bar{x} \pm s$ 2.8 ± 0.8 3.0 ± 0.8 <0.001

Table 3

Comparisons of effectiveness by different cardiovascular screening strategies"

Measures Strategy 1
vs.
Non-screening		 Strategy 2
vs.
Non-screening		 Strategy 3
vs.
Non-screening		 Strategy 2
vs.
Strategy 1		 Strategy 2
vs.
Strategy 3
Total numbers for screening 202 179 202 179 141 729
Total numbers for lifestyle intervention 74 221 68 013 65 786
Total numbers for medication treatment 35 572 17 881 17 650
QALYs gained 1 433
(969, 1 831)		 1 401
(936, 1 807)		 716
(265, 1 111)		 -32
(-143, 76)		 685
(601, 771)
Life years gained 746
(395, 998)		 695
(379, 927)		 548
(242, 771)		 -51
(-89, 4)		 148
(130, 167)
CVD events could be prevented 1 310
(782, 1 773)		 1 344
(776, 1 853)		 321
(-238, 820)		 34
(-126, 182)		 1 023
(892, 1 150)
CVD deaths could be prevented 150
(80, 201)		 140
(76, 186)		 109
(49, 155)		 -10
(-18, 1)		 30
(27, 34)
All deaths could be prevented 150
(79, 199)		 140
(76, 185)		 109
(48, 153)		 -10
(-18, 1)		 30
(27, 34)
NNS per QALY 141
(110, 209)		 144
(112, 216)		 198
(127, 529)		 3
(-9, 19)		 -54
(-313, -15)
NNS per CVD event prevented 154
(114, 259)		 150
(109, 261)		 441
(-3 655, 4 167)		 -4
(-26, 23)		 -291
(-3 980, 3 870)
NNS per CVD death prevented 1 351
(1 008, 2 521)		 1 449
(1 084, 2 630)		 1 298
(916, 2 864)		 98
(-14, 225)		 151
(-284, 186)

Figure 2

One-way sensitivity analyses on quality adjusted life years (QALYs) by different incidence rates Strategy 0, non-screening; Strategy 1, screening strategy based on cardiovascular risk charts by numbers of risk factors in adults aged 40-74 years; Strategy 2, screening strategy based on the prediction for atherosclerotic cardiovascular disease risk in China (China-PAR) models in adults aged 40-74 years; Strategy 3, screening strategy based on China-PAR models in adults aged 50-74 years."

[1] Owen AJ, Reid CM. Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease[J]. Cochrane Database Syst Rev, 2016,2016(1): CD010411.
[2] Brainin M, Sliwa K. WSO and WHF joint position statement on population-wide prevention strategies[J]. Lancet, 2020,396(10250):533-534.
doi: 10.1016/S0140-6736(20)31752-9
[3] 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中华预防医学杂志, 2019,53(1):13-35.
[4] 中华医学会心血管病学分会, 中国康复医学会心脏预防与康复专业委员会, 中国老年学和老年医学会心脏专业委员会, 等. 中国心血管病一级预防指南[J]. 中华心血管病杂志, 2020,48(12):1000-1038.
[5] Xu G, Ma M, Liu X, et al. Is there a stroke belt in China and why?[J]. Stroke, 2013,44(7):1775-1783.
doi: 10.1161/STROKEAHA.113.001238
[6] 司亚琴, 唐迅, 张杜丹, 等. 北方农村人群心血管病一级预防筛查策略的评价[J]. 北京大学学报(医学版), 2018,50(3):443-449.
[7] 刘秋萍, 高培, 唐迅, 等. 马尔可夫模型在流行病学筛查成本效果分析中的应用[J]. 中华流行病学杂志, 2021,42(4):728-734.
[8] Gu D, He J, Coxson PG, et al. The cost-effectiveness of low-cost essential antihypertensive medicines for hypertension control in China: A modelling study[J]. PLoS Med, 2015,12(8):e1001860.
doi: 10.1371/journal.pmed.1001860
[9] Lin H, Tang X, Shen P, et al. Using big data to improve cardiovascular care and outcomes in China: A protocol for the Chinese electronic health records research in Yinzhou (CHERRY) study[J]. BMJ Open, 2018,8(2):e019698.
doi: 10.1136/bmjopen-2017-019698
[10] Zhang D, Tang X, Shen P, et al. Multimorbidity of cardiometabolic diseases: Prevalence and risk for mortality from one million Chinese adults in a longitudinal cohort study[J]. BMJ Open, 2019,9(3):e024476.
doi: 10.1136/bmjopen-2018-024476
[11] Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: Systematic review and meta-analysis[J]. BMJ, 2017,359:j4849.
[12] Tan CE, Glantz SA. Association between smoke-free legislation and hospitalizations for cardiac, cerebrovascular, and respiratory diseases: A meta-analysis[J]. Circulation, 2012,126(18):2177-2183.
doi: 10.1161/CIRCULATIONAHA.112.121301
[13] Lim SH, Tai BC, Yuan JM, et al. Smoking cessation and mortality among middle-aged and elderly Chinese in Singapore: the Singapore Chinese health study[J]. Tob Control, 2013,22(4):235-240.
doi: 10.1136/tobaccocontrol-2011-050106 pmid: 22170337
[14] Adler AJ, Taylor F, Martin N, et al. Reduced dietary salt for the prevention of cardiovascular disease[J]. Cochrane Database Syst Rev, 2014,2014(12): CD009217.
[15] Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease[J]. N Engl J Med, 2016,374(21):2032-2043.
doi: 10.1056/NEJMoa1600177
[16] Shah AD, Langenberg C, Rapsomaniki E, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people[J]. Lancet Diabetes Endocrinol, 2015,3(2):105-113.
doi: 10.1016/S2213-8587(14)70219-0
[17] Emerging Risk Factors Collaboration, Di Angelantonio E, Kaptoge S, et al. Association of cardiometabolic multimorbidity with mortality[J]. JAMA, 2015,314(1):52-60.
doi: 10.1001/jama.2015.7008 pmid: 26151266
[18] Kypridemos C, Allen K, Hickey G L, et al. Cardiovascular screening to reduce the burden from cardiovascular disease: Microsimulation study to quantify policy options[J]. BMJ, 2016,353:i2793.
[19] 中国心血管病预防指南(2017)写作组, 中华心血管病杂志编辑委员会. 中国心血管病预防指南(2017)[J]. 中华心血管病杂志, 2018,46(1):10-25.
[20] Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data[J]. Lancet Diabetes Endocrinol, 2015,3(7):514-525.
doi: 10.1016/S2213-8587(15)00040-6 pmid: 26028594
[21] Li X, Wu C, Lu J, et al. Cardiovascular risk factors in China: A nationwide population-based cohort study[J]. Lancet Public Health, 2020,5(12):e672-e681.
doi: 10.1016/S2468-2667(20)30191-2
[22] Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. Circulation, 2019,140(11):e596-e646.
doi: 10.1161/CIR.0000000000000678
[1] GUO Zi-ning, LIANG Zhi-sheng, ZHOU Yi, ZHANG Na, HUANG Jie. Genetic study of cardiovascular disease subtypes defined by International Classification of Diseases [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 453-459.
[2] Jia-li CHEN,Yue-bo JIN,Yi-fan WANG,Xiao-ying ZHANG,Jing LI,Hai-hong YAO,Jing HE,Chun LI. Clinical characteristics and risk factors of cardiovascular disease in patients with elderly-onset rheumatoid arthritis: A large cross-sectional clinical study [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1040-1047.
[3] Le GAO,Shu-qing YU,Ji-chun YANG,Jun-ling MA,Si-yan ZHAN,Feng SUN. Quality assessment of global guidelines on colorectal cancer screening [J]. Journal of Peking University(Health Sciences), 2019, 51(3): 548-555.
[4] YANG Chao, WANG Jin-wei, YANG Yao-zheng, BAI Kun-hao, GAO Bi-xia, ZHAO Ming-hui, ZHANG Lu-xia, WU Shou-ling， WANG Fang. Impact of anemia and chronic kidney disease on the risk of cardiovascular disease and all-cause mortality among diabetic patients [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 495-500.
[5] SI Ya-qin, TANG Xun, ZHANG Du-dan, HE Liu, CAO Yang, WANG Jin-wei, LI Na, LIU Jian-jiang, GAO Pei, HU Yong-hua. Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 443-449.
[6] TANG Xun1, ZHANG Du-dan, HE Liu, CAO Yang, WANG Jin-wei, LI Na, HUANG Shao-ping, DOU Hui-dong, GAO Pei， HU Yong-hua. Application of the China-PAR risk prediction model for atherosclerotic cardiovascular disease in a rural northern Chinese population [J]. Journal of Peking University(Health Sciences), 2017, 49(3): 439-445.
[7] GAO Ying, ZHU Cheng-gang, WU Na-qiong, GUO Yuan-lin, LIU Geng, DONG Qian, LI Jian-jun. Study on the reliability of CardioChek PA for measuring lipid profile [J]. Journal of Peking University(Health Sciences), 2016, 48(3): 523-528.
[8] GAO Ming-Yue, YANG Min, KUANG Wei-Hong, QIU Pei-Yuan. Factors and validity analysis of Mini-Mental State Examination in Chinese elderly people [J]. Journal of Peking University(Health Sciences), 2015, 47(3): 443-449.
[9] YU Yang, SHENG Qin-Hui, ZHANG Bao-Wei, DING Wen-Hui. Left atrial size predicts adverse cardiac events in patients with non-obstruction hypertrophic cardiomyopathy [J]. Journal of Peking University(Health Sciences), 2014, 46(2): 207-210.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[6] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(4): 346 -350 .
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd